rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VERU
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Veru presents data on enobosarm for obesity treatment
      Nov 17Investing.comVERU
      Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
      Nov 9Yahoo FinanceVERU
      Why is Veru stock gaining today?
      Oct 14Investing.comVERU
      Oppenheimer reiterates Veru stock rating ahead of obesity trial data
      Oct 14Investing.comVERU
      Veru at 12th Annual Cantor Fitzgerald Global Healthcare Conference: muscle focus
      Sep 9Investing.comVERU
      Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

      --New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant met

      Sep 8Yahoo FinanceVERU
      Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

      MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming 2026 Cantor Global Healthcare Conference, in New York City, New York, on September 9, 2026 from 2:10 pm – 2:40 pm Easte

      Sep 2Yahoo FinanceVERU

      This is the newest page. Registered accounts read further back.